Neuropharmacological potential of Ceriscoides turgida (Roxb.) leaf and root in mice

The interaction of Suk-Saiyasna remedy with GABAA and CB1 receptor-targeting drugs: Enhancing hypnotic and sedative effects in in vivo models

The Suk-Saiyasna remedy, an herbal treatment, was historically used but ceased due to its cannabis content. After a relaxation of drug control laws in Thailand, its use re-emerged. This study examines the Suk-Saiyasna remedy's impact on rodent behavior and its receptor effects. This study was conducted to assess the sedative-like effects of the remedy on mice. The mice were divided into groups receiving 0.6, 3, 30, and 60 mg/kg extracts, with negative controls for comparison. We also investigated the impact on receptors, utilizing negative controls and pretreatment with receptor blockers, followed by either a negative control or a 60 mg/kg extract. Furthermore, this study investigated the behavioral aspects of mice, including anxiolytic effects, antidepressant-like effects, and motor coordination, utilizing the elevated plus-maze, open-field, and rotarod performance tests. The Suk-Saiyasna remedy (P < 0.05) decreased significantly in the latent period and increased sleeping time in the treated groups. Moreover, the Suk-Saiyasna remedy also showed efficacy in reaction to GABAA receptors and cannabinoid CB1 receptors (P < 0.05). In addition, positive effects were observed regarding the animal behavior in the arena, as the animal activity, behavior, and muscle coordination were reduced (P < 0.05). The Suk-Saiyasna remedy may be involved in a sedative-hypnotic-like effect in rodents under normal conditions through the modulation of GABAergic neurons and induction of the cannabinoid CB1 receptor mechanism.

Serotonergic and noradrenergic response of ethanol extract; opioidergic response of ethyl acetate extract of Dicranopteris linearis L. leaf

Background

Dicranopteris linearis L. is among the popular tribal plants used for various ailments, although many of its pharmacological potentials have not been investigated yet. The neuropharmacological potentials of the leaf, including sedative-anxiolytic potential, were previously studied however, the antidepressant activity was yet to be examined. Thus, this study was aimed to investigate the serotonergic, noradrenergic and opioidergic response of D. linearis leaf extracts.

Methods

The plant leaf was extracted in three solvents- water (DLAQ), ethanol (DLET) and ethyl acetate (DLEA) and applied each in 200 and 400 mg.kg− 1 per body weight of Swiss Albino mice. Forced Swim Test (FST) and Tail Suspension Test (TST) were conducted to evaluate antidepressant potential. In FST, latency and duration of immobility, swimming and climbing time were recorded. In TST, immobility, swinging, curling and pedaling were observed. Alongside, preliminary screening through acute toxicity study and pentobarbitone induced sleep test were performed.

Results

Both in FST and TST, the duration of immobility was reduced by the standard imipramine and DLET 200 and 400. In FST, DLEA 200 and 400 increased the climbing time suggesting noradrenergic mechanism of action and decreased the swimming time suggesting deficit of serotoninergic mechanism of action. Interestingly, DLET increased both the parameters presenting a dual action. However, in TST, DLEA decreased immobility but increased swinging and curling response which indicated its opioidergic mechanism. On the other hand, DLET proved to mediate through serotonin and/or NA reuptake mechanism by having decreased curling time.

Conclusion

Among the three extracts, the ethanol extract proved to be more potent. DLET mimicked the standard imipramine in all parameters except for the curling behavior. The result thus suggests D. linearis as a potent antidepressant agent however, recommends its medicinal use after further investigation to identify bioactive compounds.

In Vivo Neuropharmacological Potential of Gomphandra tetrandra (Wall.) Sleumer and In-Silico Study against β-Amyloid Precursor Protein

Medicinal plants possess a surplus of novel and biologically active secondary metabolites that are responsible for counteracting diseases. Traditionally, Gomphandra tetrandra (Wall.) Sleumer is used to treat mental disorders. The present research was designed to explore phytochemicals from the ethanol leaf extract of Gomphandra tetrandra (Wall.) Sleumer to identify the potential pharmacophore(s) in the treatment of neurological disorders. The chemical compounds of the experimental plant were identified through GC-MS analysis. In-vitro antioxidant activity was assessed using different methods. Furthermore, in-vivo neurological activity was assessed in Swiss-albino mice. Computer-aided analysis was appraised to determine the best-fit phytoconstituent of a total of fifteen identified compounds in the experimental plant extract against beta-amyloid precursor protein. The experimental extract revealed fifteen compounds in GC-MS analysis and the highest content was 9, 12, 15-octadecatrienoic acid (z,z,z). The extract showed potent antioxidant activity in in-vitro assays. Furthermore, in in-vivo neurological assays, the extract disclosed significant (p < 0.05) neurological activity. The most favorable phytochemicals as neurological agents were selected via ADMET profiling, and molecular docking was studied with beta-amyloid precursor protein. In the computer-aided study, 1, 5-diphenyl-2h-1, 2, 4-triazoline-3-thione (Pub Chem CID: 2802516) was more active than other identified compounds with strong binding affinity to beta-amyloid precursor protein. The present in vivo and in silico studies revealed neuropharmacological features of G. tetrandra leaf extract as a natural agent against neurological disorders, especially Alzheimer’s disease.